EA200301295A1 - Полипептид, его конъюгат с доксорубицином и фармацевтическая композиция на его основе - Google Patents

Полипептид, его конъюгат с доксорубицином и фармацевтическая композиция на его основе

Info

Publication number
EA200301295A1
EA200301295A1 EA200301295A EA200301295A EA200301295A1 EA 200301295 A1 EA200301295 A1 EA 200301295A1 EA 200301295 A EA200301295 A EA 200301295A EA 200301295 A EA200301295 A EA 200301295A EA 200301295 A1 EA200301295 A1 EA 200301295A1
Authority
EA
Eurasian Patent Office
Prior art keywords
conjugate
polypeptide
inventive
pharmaceutical composition
growth factor
Prior art date
Application number
EA200301295A
Other languages
English (en)
Other versions
EA005865B1 (ru
Inventor
Евгений Сергеевич СЕВЕРИН
Сергей Евгеньевич СЕВЕРИН
Сергей Викторович Луценко
Сергей Михайлович Киселев
Наталья Борисовна Фельдман
Original Assignee
Закрытое Акционерное Общество "Русские Биотехнологии"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Закрытое Акционерное Общество "Русские Биотехнологии" filed Critical Закрытое Акционерное Общество "Русские Биотехнологии"
Publication of EA200301295A1 publication Critical patent/EA200301295A1/ru
Publication of EA005865B1 publication Critical patent/EA005865B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Предложен полипептид, являющийся аналогом фрагмента эпидермального фактора роста с 21 по 31 аминокислоту, способный эффективно связываться с рецептором эпидермального фактора роста, в качестве вектора для направленной доставки противоопухолевых препаратов в опухолевые клетки. Предложен также конъюгат полипептида с доксорубицином, обладающий избирательным действием в отношении раковых опухолей и способный значительно снижать резистентность опухолевых клеток к противовопухолевым препаратам, в котором конъюгированные части соединены неустойчивой к гидролизу химической связью. Фармацевтическая композиция содержит эффективное количество конъюгата и носитель, пригодный для внутривенного введения. Изобретение может быть использовано в медицине для лечения онкологических больных.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200301295A 2001-12-21 2002-12-20 Аналог фрагмента эпидермального фактора роста, его конъюгат с доксорубицином и фармацевтическая композиция на основе конъюгата EA005865B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2001134536/14A RU2196604C1 (ru) 2001-12-21 2001-12-21 Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
PCT/RU2002/000544 WO2003053457A1 (fr) 2001-12-21 2002-12-20 Polypeptide, son conjugue avec doxorubicine et composition pharmaceutique sur cette base

Publications (2)

Publication Number Publication Date
EA200301295A1 true EA200301295A1 (ru) 2004-10-28
EA005865B1 EA005865B1 (ru) 2005-06-30

Family

ID=20254793

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200301295A EA005865B1 (ru) 2001-12-21 2002-12-20 Аналог фрагмента эпидермального фактора роста, его конъюгат с доксорубицином и фармацевтическая композиция на основе конъюгата

Country Status (13)

Country Link
US (1) US7368431B2 (ru)
EP (1) EP1466614B1 (ru)
JP (1) JP2005513108A (ru)
CN (1) CN1281270C (ru)
AT (1) ATE411051T1 (ru)
AU (1) AU2002362210B9 (ru)
CA (1) CA2451993A1 (ru)
DE (1) DE50212918D1 (ru)
EA (1) EA005865B1 (ru)
HK (1) HK1076601A1 (ru)
NZ (1) NZ533849A (ru)
RU (1) RU2196604C1 (ru)
WO (1) WO2003053457A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100824396B1 (ko) * 2006-10-10 2008-04-22 (주)케어젠 상피세포 성장인자의 활성을 가지는 펩타이드 및 그의 용도
WO2009059450A1 (en) * 2007-11-05 2009-05-14 Shanghai Jiaotong University Peptide ligand directed drug delivery
CN101274100B (zh) * 2008-02-20 2010-11-24 中山大学 一种阿霉素-二肽复合物的制备方法和应用
DE102008050347B4 (de) * 2008-10-02 2011-01-20 Siemens Aktiengesellschaft Verfahren, Magnetresonanzanlage und Datenträger zur Bestimmung eines Nierenfunktionsparameters
CN102905762B (zh) 2010-04-29 2017-02-15 陶氏环球技术有限责任公司 用于诱导饱腹感的方法和组合物
CN110386962A (zh) * 2019-07-04 2019-10-29 苏州强耀生物科技有限公司 一种阿霉素偶联靶向多肽的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69719A0 (en) * 1983-09-14 1983-12-30 Yeda Res & Dev Synthetic peptides with egf like activity
CA1275922C (en) 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
IN165717B (ru) 1986-08-07 1989-12-23 Battelle Memorial Institute
FI102355B (fi) 1988-02-11 1998-11-30 Squibb Bristol Myers Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjug aattien valmistamiseksi
DE4002888A1 (de) * 1990-02-01 1991-08-08 Behringwerke Ag Anthracyclin-glycosyl-prodrugs, verfahren zu ihrer herstellung und ihre verwendung in kombination mit funktionalisierten tumorspezifischen enzymkonjugaten
US5137877B1 (en) 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
US5183805A (en) 1990-08-13 1993-02-02 Board Of Regents, The University Of Texas System Bioactive egf peptides for promotion of tissue regeneration and cancer therapy
GB9026491D0 (en) * 1990-12-05 1991-01-23 Erba Carlo Spa Anthracycline-conjugates
US5776458A (en) 1990-12-05 1998-07-07 Pharmacia & Upjohn S.P.A. Anthracycline-conjugates
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
US5393737A (en) 1992-08-20 1995-02-28 Health Research, Inc. Cytotoxic drug conjugates for treatment of neoplastic diseases
GB9500660D0 (en) * 1995-01-13 1995-03-08 Secr Defence Growth factor anologs
ATE234635T1 (de) * 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler

Also Published As

Publication number Publication date
EP1466614A4 (de) 2006-05-24
US20050070465A1 (en) 2005-03-31
AU2002362210A1 (en) 2003-07-09
CA2451993A1 (en) 2003-07-03
JP2005513108A (ja) 2005-05-12
RU2196604C1 (ru) 2003-01-20
CN1606450A (zh) 2005-04-13
EA005865B1 (ru) 2005-06-30
DE50212918D1 (de) 2008-11-27
AU2002362210B2 (en) 2008-04-03
AU2002362210B9 (en) 2008-08-21
AU2002362210B8 (en) 2008-04-24
ATE411051T1 (de) 2008-10-15
NZ533849A (en) 2006-09-29
EP1466614B1 (de) 2008-10-15
EP1466614A1 (de) 2004-10-13
WO2003053457A1 (fr) 2003-07-03
WO2003053457A8 (fr) 2004-09-16
CN1281270C (zh) 2006-10-25
US7368431B2 (en) 2008-05-06
HK1076601A1 (en) 2006-01-20

Similar Documents

Publication Publication Date Title
HRP20151172T1 (hr) Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
MXPA05005330A (es) Composiciones y formulaciones de gastrina, y metodos de uso y preparacion.
EP0740650A4 (en) CO-MEDICINAL PRODUCTS USED AS A REGULATED MEDICINE DELIVERY PROCESS
HUP0300421A2 (hu) Kezelési eljárás ligand-immunogén konjugátumok felhasználásával
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
EP1626055A3 (en) Non-mammalian GnRH analogs and uses thereof in the regulation of the immune system
WO2004076644A3 (en) A composition for delivering an agent to a target cell and uses thereof
MXPA03005394A (es) Composiciones que contienen complejos de inclusion.
DE60006100D1 (de) Lang wirkende insulinotrope peptide
HK1120427A1 (en) Anti-glypican-3 antibody
HK1076601A1 (en) Polypeptide, the conjugate thereof with doxorubicine and a pharmaceutical composition based thereon
JP2005537234A5 (ru)
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
MX2022009819A (es) Moleculas de union al antigeno anti-grupo de diferenciacion 137 (cd137) para usarse en el tratamiento contra el cancer.
AU2599002A (en) Fusion cells and cytokine compositions for treatment of disease
AR016427A1 (es) CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
BR0213821A (pt) Conjugados de polìmero/peptìdeo timosina alfa 1
MXPA02008870A (es) Novedosos antagonistas de lhrh, produccion de los mismos y sus uso como medicamentos.
DE69837915D1 (de) Zusammensetzung aus liganden/lytischen petiden und ihre verwendung
DE60331827D1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
ATE293991T1 (de) VERWENDUNG EINES MIT DEM PEPTID ßELAGIGILTVß ASSOZIIERTEN ENTEROBAKTERIEN-PROTEINS OMPA ZUR BEHANDLUNG VON MELANOMEN
CA2447391A1 (en) Substantially homogeneous bio-affecting material having a pre-determined ratio of transferrin to doxorubicin, its method of manufacture and its method of use
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ KG TJ TM

PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY MD RU